ERBB2 and gastric cancer: The results of the second-phase clinical trial DESTINY-Gastric02 demonstrated that T-DXd monotherapy exhibited remarkable efficacy as a second-line treatment for patients with HER2-positive advanced gastric cancer(ORR 41.8%, overall survival (OS)>1 year).